Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Hoffmann-La Roche
Columbia University
Olivia Newton-John Cancer Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Tata Memorial Hospital
University of Utah
Institut du Cancer de Montpellier - Val d'Aurelle
Imperial College London
Imperial College London
Imperial College London
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
University of Alberta
Crinetics Pharmaceuticals Inc.
Amgen
National Cancer Center, Korea
Merck Sharp & Dohme LLC
University of California, San Francisco
Australasian Gastro-Intestinal Trials Group
Hutchmed
Grupo Espanol de Tumores Neuroendocrinos
University Hospital, Bordeaux
University of Iowa
University of Pittsburgh
Azienda USL Reggio Emilia - IRCCS
Grupo Espanol de Tumores Neuroendocrinos
Erasmus Medical Center
Orano Med LLC
Instituto do Cancer do Estado de São Paulo
University of Alberta
Melanoma and Skin Cancer Trials Limited
EpicentRx, Inc.
Peking University
Clarity Pharmaceuticals Ltd
Latin American Cooperative Oncology Group
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Grupo Espanol de Tumores Neuroendocrinos
Grupo Espanol de Tumores Neuroendocrinos
Beijing Chest Hospital